Standigm and SK Chemicals Repurpose FDA-approved Drug into Rheumatoid Arthritis Candidate and Apply for Patent through their Open Innovation Partnership
Summary
SK Chemicals has shared their expertise in these diseases and validated the predicted targets and compounds through in vitro and in vivo studies. We will continue to expand our collaboration to address unmet needs in treating intractable diseases.” Standigm is an AI-driven drug discovery company. Founded in 2015, Standigm has raised $23M from leading investors and developed an elite team with multi-disciplinary expertise in chemistry, biology, pharmacology, artificial intelligence, and data structures to ease the pains of patients all over the world. SK Chemicals’ life sciences business is dominated by pharmaceuticals and biologics and is aimed at providing comprehensive healthcare solutions that cover patient care from diagnosis to treatment and prevention. SK Chemicals successfully developed the first new drug in Korea, Sunpla®, in 1999, thereby opening up a new chapter in the field of synthetic new medicines.